308 lines
12 KiB
Plaintext
308 lines
12 KiB
Plaintext
English French Notes Complete/Exclude
|
|
528 FINE NEEDLE ASPIRATION......
|
|
529 CORE NEEDLE BIOPSY..........
|
|
530 INCISIONAL BIOPSY...........
|
|
531 EXCISIONAL BIOPSY...........
|
|
518OUTSIDE CONFIRMATION OF BIOPSY
|
|
PRIMARY SITE..................:
|
|
HISTOLOGY/BEHAVIOR CODE.......:
|
|
520ADDNL GRADE CODING SYSTEM.....
|
|
521VALUE OF ADDNL CODING SYSTEM..
|
|
26DIAGNOSTIC CONFIRMATION.......
|
|
PRETREATMENT TUMOR SIZE (mm)
|
|
PATHOLOGIC TUMOR SIZE (mm)
|
|
DEPTH OF TUMOR
|
|
29PRETREATMENT TUMOR SIZE (mm)...
|
|
522PATHOLOGIC TUMOR SIZE (mm).....
|
|
523DEPTH OF TUMOR.................
|
|
CONSULTATIONS:
|
|
524 MEDICAL ONCOLOGIST...........
|
|
525 RADIATION ONCOLOGIST.........
|
|
TREATING SURGEON................: Not applicable, no surgery
|
|
ASA CLASS.......................: Class unknown or not applicable
|
|
POSTOPERATIVE DEATH.............: Not applicable, no surgery
|
|
526 TREATING SURGEON................
|
|
527 ASA CLASS.......................
|
|
441 POSTOPERATIVE DEATH.............
|
|
EXTERNAL BEAM RADIATION.........: No
|
|
INTRAOPERATIVE RADIATION........: No
|
|
EXTERNAL BEAM RADIATION.........: Unknown
|
|
INTRAOPERATIVE RADIATION........: Unknown
|
|
532 EXTERNAL BEAM RADIATION.........
|
|
533 NUMBER OF FRACTIONS...........
|
|
534 RADIATION ENERGY (MV).........
|
|
567 DATE THERAPY STARTED..........
|
|
361 DATE THERAPY ENDED............
|
|
535 INTRAOPERATIVE RADIATION........
|
|
537 RADIATION ENERGY (MV).........
|
|
539 NUMBER OF DAYS GIVEN..........
|
|
541 DATE THERAPY STARTED..........
|
|
542 DATE THERAPY ENDED............
|
|
51.3 RADIATION/SURGERY SEQUENCE......
|
|
NUMBER OF FRACTIONS...........: 000
|
|
RADIATION ENERGY (MV).........: 00
|
|
DATE THERAPY STARTED..........: 00/00/0000
|
|
DATE THERAPY ENDED............: 00/00/0000
|
|
NUMBER OF FRACTIONS...........: 999
|
|
RADIATION ENERGY (MV).........: 99
|
|
DATE THERAPY STARTED..........: 99/99/9999
|
|
DATE THERAPY ENDED............: 99/99/9999
|
|
NUMBER OF DAYS GIVEN..........: 000
|
|
NUMBER OF DAYS GIVEN..........: 999
|
|
DATE OF CHEMOTHERAPY............:
|
|
AGENTS ADMINISTERED, METHODS OF DELIVERY AND LOCATIONS:
|
|
CISPLATIN.........: No DOXORUBICIN.......: No
|
|
METHOD OF DELIVERY: Not applicable METHOD OF DELIVERY: Not applicable
|
|
LOCATION..........: Not applicable LOCATION..........: Not applicable
|
|
CYTOXAN...........: No ETOPOSIDE.........: No
|
|
DTIC..............: No IFOSFAMIDE........: No
|
|
METHOD OF DELIVERY..............: Not applicable
|
|
LOCATION........................: Not applicable
|
|
METHOD OF DELIVERY..............: Unknown
|
|
547 METHOD OF DELIVERY..............
|
|
548 METHOD OF DELIVERY..............
|
|
549 METHOD OF DELIVERY..............
|
|
550 METHOD OF DELIVERY..............
|
|
551 METHOD OF DELIVERY..............
|
|
552 METHOD OF DELIVERY..............
|
|
559 COLONY STIMULATING FACTORS......
|
|
560 NATIONAL TREATMENT PROTOCOL.....
|
|
561 OTHER PROTOCOL..................
|
|
562 REFERRED TO REHAB SERVICES......
|
|
563 CONSULT W PHYSICAL THERAPY/REHAB
|
|
564 TRANSFERRED TO REHAB FACILITY...
|
|
565 NO OF HOSPITALIZATIONS W/I 6 MO.
|
|
566 TOTAL LENGTH OF STAYS...........
|
|
DISTANT SITE(S) OF RECURRENCE
|
|
SUBSEQUENT TREATMENT FOR RECURRENCE OR PROGRESSION
|
|
TABLE V - FIRST RECURRENCE AND SUBSEQUENT TREATMENT
|
|
NO SUBSEQUENT TREATMENT
|
|
.07 HORMONE THERAPY
|
|
ACCESSION NUMBER..................:
|
|
SEQUENCE NUMBER...................:
|
|
POSTAL CODE AT DIAGNOSIS..........:
|
|
DATE OF BIRTH.....................:
|
|
RACE..............................:
|
|
SPANISH ORIGIN....................:
|
|
SEX...............................:
|
|
PRIMARY PAYER AT DIAGNOSIS........:
|
|
FAMILY HIST OF SOFT TISSUE SARCOMA:
|
|
PERSONAL HISTORY OF ANY CANCER....:
|
|
CLASS OF CASE.....................:
|
|
ANGIOGRAM OF PRIMARY............:
|
|
BONE MARROW ASPIRATE/BIOPSY.....:
|
|
BONE SCAN.......................:
|
|
CT SCAN OF CHEST................:
|
|
CT SCAN OF PRIMARY..............:
|
|
LIVER FUNCTION STUDIES..........:
|
|
MRI OF PRIMARY..................:
|
|
MRI OF OTHER....................:
|
|
ELECTRON MICROSCOPY.............:
|
|
FLOW CYTOMETRY..................:
|
|
IN SITU HYBRIDIZATION...........:
|
|
BIOPSIES: HISTOLOGY/BEHAVIOR/GRADE
|
|
FINE NEEDLE ASPIRATION..........:
|
|
CORE NEEDLE ASPIRATION..........:
|
|
INCISIONAL BIOPSY...............:
|
|
EXCISIONAL BIOPSY...............:
|
|
OUTSIDE CONFIRMATION OF BIOPSY....:
|
|
DATE OF INITIAL DIAGNOSIS.........:
|
|
PRIMARY SITE......................:
|
|
SUBSITE...........................:
|
|
HISTOLOGY/BEHAVIOR CODE...........:
|
|
GRADE.............................:
|
|
ADDNL GRADE CODING SYSTEM.........:
|
|
VALUE OF ADDNL CODING SYSTEM......:
|
|
DIAGNOSTIC CONFIRMATION...........:
|
|
PRETREATMENT TUMOR SIZE (mm)......:
|
|
PATHOLOGIC TUMOR SIZE (mm)........:
|
|
DEPTH OF TUMOR....................:
|
|
MULTIFOCAL........................:
|
|
REGIONAL NODES EXAMINED...........:
|
|
REGIONAL NODES POSITIVE...........:
|
|
SITE OF DISTANT METASTASIS #1...:
|
|
SITE OF DISTANT METASTASIS #2...:
|
|
SITE OF DISTANT METASTASIS #3...:
|
|
AJCC STAGE......................:
|
|
CLINICAL STAGED BY..............:
|
|
PATHOLOGIC STAGED BY............:
|
|
MEDICAL ONCOLOGIST..............:
|
|
RADIATION ONCOLOGIST............:
|
|
Print Soft Tissue Sarcoma PCE
|
|
PCE Study of Soft Tissue Sarcoma
|
|
FIRST COURSE TREATMENT DATE.......:
|
|
RESIDUAL PRIMARY TUMOR..........:
|
|
TREATING SURGEON................:
|
|
ASA CLASS.......................:
|
|
POSTOPERATIVE DEATH.............:
|
|
EXTERNAL BEAM RADIATION...:
|
|
BRACHYTHERAPY...........:
|
|
NUMBER OF FRACTIONS.......:
|
|
NUMBER OF DAYS GIVEN....:
|
|
DOSE....................:
|
|
RADIATION ENERGY (MV).....:
|
|
DATE THERAPY STARTED....:
|
|
DATE THERAPY STARTED......:
|
|
DATE THERAPY ENDED......:
|
|
DATE THERAPY ENDED........:
|
|
INTRAOPERATIVE RADIATION..:
|
|
RADIATION/SURGERY SEQUENCE:
|
|
DATE OF CHEMOTHERAPY:
|
|
AGENT ADMINISTERED METHOD OF DELIVERY LOCATION
|
|
COLONY STIMULATION FACTOR........:
|
|
NATIONAL TREATMENT PROTOCOL......:
|
|
OTHER PROTOCOL...................:
|
|
REFERRED TO REHAB SERVICES.......:
|
|
CONSULT W PHYSICAL THERAPY/REHAB.:
|
|
TRANSFERRED TO REHAB FACILITY....:
|
|
NO OF HOSPITALIZATIONS W/I 6 MO..:
|
|
TOTAL LENGTH OF STAYS............:
|
|
TYPE OF FIRST RECURRENCE..........:
|
|
OTHER TYPE OF FIRST RECURRENCE....:
|
|
DISTANT SITE(S) OF FIRST RECURRENCE:
|
|
RECURRENCE SITE 1.................:
|
|
RECURRENCE SITE 2.................:
|
|
RECURRENCE SITE 3.................:
|
|
NO SUBSEQUENT TREATMENT
|
|
HORMONE THERAPY:
|
|
SURGERY OF PRIMARY SITE DATE...:
|
|
SCOPE OF LYMPH NODE SURGERY...:
|
|
RECON/RESTORE - DELAYED.......:
|
|
RECON/RESTORE - DELAYED DATE..:
|
|
too long:
|
|
Text should not exceed NAACCR length of
|
|
Do you want to re-edit this field
|
|
Patient Care Evaluation Study of Thyroid Cancer
|
|
FAMILY HISTORY OF THYROID CANCER
|
|
PERSONAL HISTORY OF NON-THYROID CANCER
|
|
PRIOR EXPOSURE TO RADIATION
|
|
PERSONAL HISTORY OF GOITER
|
|
FAMILY HISTORY OF THYROID DISEASE
|
|
PERSONAL HISTORY OF GRAVES DISEASE
|
|
PERSONAL HISTORY OF THYROIDITIS
|
|
FAMILY HISTORY OF GOITER OR OTHER THYROID DISEASE
|
|
9POSTAL CODE AT DIAGNOSIS..........
|
|
9SPANISH ORIGIN....................
|
|
18PRIMARY PAYER AT DIAGNOSIS........
|
|
400FAMILY HISTORY OF THYROID CANCER..
|
|
PERSONAL HISTORY OF NON-THYROID CANCER:
|
|
402 CHILDHOOD MALIGNANCY............
|
|
403PRIOR EXPOSURE TO RADIATION.......
|
|
404PERSONAL HISTORY OF GOITER........
|
|
405FAMILY HISTORY THYROID DISEASE....
|
|
406PERSONAL HISTORY OF GRAVES DISEASE
|
|
407PERSONAL HISTORY OF THYROIDITIS...
|
|
SYMPTOMS/SIGNS PRESENT
|
|
DIAGNOSTIC/SURGICAL WORKUP
|
|
HISTOLOGY/BEHAVIOR CODE (ICD-O-2)
|
|
BLOOD VESSEL INVASION
|
|
EXTRA-THYROID EXTENSION
|
|
SYMPTOMS/SIGNS PRESENT:
|
|
409 HOARSENESS OR VOICE CHANGE.....
|
|
410 NECK NODAL MASS................
|
|
413 PATHOLOGIC FRACTURE............
|
|
414 STRIDOR OR DIFFICULTY BREATHING
|
|
415 THYROID MASS...................
|
|
416 WEIGHT LOSS....................
|
|
DIAGNOSTIC/SURGICAL WORKUP:
|
|
418 BONE SCAN......................
|
|
420 CT SCAN OF NECK................
|
|
422 INCISIONAL BIOPSY..............
|
|
425 NEEDLE ASPIRATION OF NECK NODE.
|
|
426 NEEDLE ASPIRATION OF THYROID...
|
|
427 MRI OF NECK....................
|
|
428 THYROID SCAN...................
|
|
429 ULTRASOUND OF THYROID..........
|
|
HISTOLOGY/BEHAVIOR CODE (ICD-O-2):
|
|
431BLOOD VESSEL INVASION............
|
|
432EXTRA-THYROIDAL EXTENSION........
|
|
SIZE OF TUMOR
|
|
LOCATION OF POSITIVE NODES
|
|
29SIZE OF TUMOR..................
|
|
434LOCATION OF POSITIVE NODES.....
|
|
19CLINICAL STAGE..................
|
|
89PATHOLOGIC STAGE................
|
|
DATE OF FIRST COURSE TREATMENT.......:
|
|
DATE OF NON CANCER-DIRECTED SURGERY:
|
|
NON CANCER-DIRECTED SURGERY........:
|
|
DATE OF SURGERY OF PRIMARY SITE....:
|
|
DATE OF DISCHARGE AFTER SURGERY....: 00/00/0000
|
|
435 DATE OF DISCHARGE AFTER SURGERY....
|
|
SURGERY OF PRIMARY SITE............:
|
|
RESIDUAL PRIMARY TUMOR.............: NA
|
|
AIRWAY PROBLEM REQ TRACHEOSTOMY..: Not applicable, no surgery
|
|
BLEEDING HEMATOMA................: Not applicable, no surgery
|
|
HYPOCALCEMIA.....................: Not applicable, no surgery
|
|
RECURRENT NERVE INJURY...........: Not applicable, no surgery
|
|
WOUND INFECTION..................: Not applicable, no surgery
|
|
POSTOPERATIVE DEATH WITH 30 DAYS.: Not applicable, no surgery
|
|
59 RESIDUAL PRIMARY TUMOR.............
|
|
436 AIRWAY PROBLEM REQ TRACHEOSTOMY..
|
|
437 BLEEDING HEMATOMA................
|
|
439 RECURRENT NERVE INJURY...........
|
|
440 WOUND INFECTION..................
|
|
441 POSTOPERATIVE DEATH WITHIN 30 DAYS.
|
|
RADIATION:
|
|
DATE RADIATION STARTED.............:
|
|
REGIONAL RAD (cGy) DOSE............: 00000
|
|
BOOST DOSAGE.......................: 00000
|
|
TOTAL MILLICURIES (mCi) OF RADIOIODINE:
|
|
INITAL DOSE........................: 00000
|
|
SECOND DOSE........................: 00000
|
|
REGIONAL RAD (cGy) DOSE............: 99999
|
|
BOOST DOSAGE.......................: 99999
|
|
INITAL DOSE........................: 99999
|
|
SECOND DOSE........................: 99999
|
|
442 REGIONAL RAD (cGy) DOSE............
|
|
443 BOOST DOSAGE.......................
|
|
444 INITIAL DOSE.......................
|
|
445 SECOND DOSE........................
|
|
ADJUVANT CHEMO W BEAM RADIATION....: No concomitant treatment
|
|
ADJUVANT CHEMO W BEAM RADIATION....: Unknown if therapy concomitant
|
|
446 ADJUVANT CHEMO W BEAM RADIATION....
|
|
THYROID HORMONE THERAPY............:
|
|
FAMILY HISTORY OF THYROID CANCER..:
|
|
CHILDHOOD MALIGNANCY............:
|
|
PRIOR EXPOSURE TO RADIATION.......:
|
|
PERSONAL HISTORY OF GOITER........:
|
|
FAMILY HISTORY OF THYROID DISEASE.:
|
|
PERSONAL HISTORY OF GRAVES DISEASE:
|
|
PERSONAL HISTORY OF THYROIDITIS...:
|
|
TABLE II - INITIAL DIAGNOSIS/CANCER IDENTIFICATION
|
|
HOARSENESS OR VOICE CHANGE......:
|
|
NECK NODAL MASS.................:
|
|
PATHOLOGIC FRACTURE.............:
|
|
STRIDOR/DIFFICULTY BREATHING....:
|
|
THYROID MASS....................:
|
|
WEIGHT LOSS.....................:
|
|
DIAGNOISTIC/SURGICAL WORKUP:
|
|
CT SCAN OF NECK.................:
|
|
NEEDLE ASPIRATION OF NECK NODE..:
|
|
NEEDLE ASPIRATION OF THYROID....:
|
|
MRI OF NECK.....................:
|
|
THYROID SCAN....................:
|
|
ULTRASOUND OF THYROID...........:
|
|
PRIMARY SITE (ICD-O-2)............:
|
|
HISTOLOGY/BEHAVIOR CODE (ICD-O-2).:
|
|
BLOOD VESSEL INVASION.............:
|
|
EXTRA-THYROIDAL EXTENSION.........:
|
|
SIZE OF TUMOR (mm)................:
|
|
LOCATION OF POSITIVE NODES........:
|
|
CLINICAL STAGE................:
|
|
PATHOLOGIC STAGE..............:
|
|
Print Thyroid PCE
|
|
PCE Study of Thyroid Cancer
|
|
DISCHARGE AFTER SURGERY DATE....:
|
|
AIRWAY PROBLEM W TRACHEOSTOMY.:
|
|
BLEEDING HEMOTOMA.............:
|
|
RECURRENT NERVE INJURY........:
|
|
WOUND INFECTION...............:
|
|
POSTOPERATIVE DEATH W/I 30 DAYS.:
|
|
REGIONAL RAD (cGy) DOSE.........:
|
|
BOOST DOSAGE....................:
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|
|
#################### #################### ####################
|